Literature DB >> 9203083

Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole.

P M Carvey1, S Pieri, Z D Ling.   

Abstract

The direct-acting dopamine (DA) agonist pramipexole (2 amino-4,5,6,7-tetrahydro-6-propyl-amino-benzthiazole-dihydrochlori de) was evaluated for its ability to attenuate levodopa-induced loss of tyrosine hydroxylase immunoreactive (THir, a marker for dopamine neurons) cells in mesencephalic cultures. Pramipexole reduced levodopa-induced THir cell loss in a dose-dependent and saturable fashion (ED50 = 500 pM), its inactive stereoisomer was significantly less potent in this regard and pergolide and bromocriptine had negligible cytoprotective effects. Culture media from mesencephalic cultures incubated with pramipexole for 6 days increased THir cell counts in freshly harvested recipient cultures. The magnitude of this effect was directly proportional to the amount of pramipexole in the donor cultures and heat-inactivation of the media abolished the growth promoting effect. The results from this exploratory set of experiments suggest that pramipexole may be cytoprotective to dopamine neurons in tissue culture. Pramipexole's affinity for DA receptors, its antioxidant action or its ability to enhance mesencephalic trophic activity could be responsible for this effect.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9203083     DOI: 10.1007/BF01273182

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  42 in total

Review 1.  Oxygen free radicals and Parkinson's disease.

Authors:  J D Adams; I N Odunze
Journal:  Free Radic Biol Med       Date:  1991       Impact factor: 7.376

2.  Exposure of striatal [corrected] synaptosomes to L-dopa increases levels of oxidized glutathione.

Authors:  M B Spina; G Cohen
Journal:  J Pharmacol Exp Ther       Date:  1988-11       Impact factor: 4.030

3.  Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease.

Authors:  D T Dexter; C J Carter; F R Wells; F Javoy-Agid; Y Agid; A Lees; P Jenner; C D Marsden
Journal:  J Neurochem       Date:  1989-02       Impact factor: 5.372

4.  Pramipexole, a dopamine D2 autoreceptor agonist, decreases the extracellular concentration of dopamine in vivo.

Authors:  A J Carter; R E Müller
Journal:  Eur J Pharmacol       Date:  1991-07-23       Impact factor: 4.432

5.  The affinities of ergot compounds for dopamine agonist and dopamine antagonist receptor sites.

Authors:  M Goldstein; J Y Lew; A Sauter; A Lieberman
Journal:  Adv Biochem Psychopharmacol       Date:  1980

6.  Neurotoxicity of levodopa on catecholamine-rich neurons.

Authors:  M A Mena; B Pardo; M J Casarejos; S Fahn; J García de Yébenes
Journal:  Mov Disord       Date:  1992       Impact factor: 10.338

7.  Dopamine autoreceptors modulate the phosphorylation of tyrosine hydroxylase in rat striatal slices.

Authors:  R S Salah; D M Kuhn; M P Galloway
Journal:  J Neurochem       Date:  1989-05       Impact factor: 5.372

8.  Pramipexole in patients with early Parkinson's disease.

Authors:  J P Hubble; W C Koller; N R Cutler; J J Sramek; J Friedman; C Goetz; A Ranhosky; D Korts; A Elvin
Journal:  Clin Neuropharmacol       Date:  1995-08       Impact factor: 1.592

9.  Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats.

Authors:  D L Felten; S Y Felten; R W Fuller; T D Romano; E B Smalstig; D T Wong; J A Clemens
Journal:  Neurobiol Aging       Date:  1992 Mar-Apr       Impact factor: 4.673

10.  In vivo comparisons of the effects of quinpirole and the putative presynaptic dopaminergic agonists B-HT 920 and SND 919 on striatal dopamine and acetylcholine release.

Authors:  G S Robertson; C S Tham; C Wilson; A Jakubovic; H C Fibiger
Journal:  J Pharmacol Exp Ther       Date:  1993-03       Impact factor: 4.030

View more
  17 in total

1.  Strategies for the protection of dopaminergic neurons against neurotoxicity.

Authors:  M Gerlach; K L Double; M B Youdim; P Riederer
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

Review 2.  Are dopamine receptor agonists neuroprotective in Parkinson's disease?

Authors:  W D Le; J Jankovic
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 3.  The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.

Authors:  T N Chase
Journal:  Drugs       Date:  1998       Impact factor: 9.546

4.  The putative neuroprotective role of dopamine agonists in Parkinson's disease.

Authors:  F Grandas
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

Review 5.  Assessing the roles of stimulants/stimulant-like drugs and dopamine-agonists in the treatment of bipolar depression.

Authors:  Bernardo Dell'Osso; Terence A Ketter; Laura Cremaschi; Gregorio Spagnolin; A Carlo Altamura
Journal:  Curr Psychiatry Rep       Date:  2013-08       Impact factor: 5.285

Review 6.  Role of pramipexole in the management of Parkinson's disease.

Authors:  Angelo Antonini; Paolo Barone; Roberto Ceravolo; Giovanni Fabbrini; Michele Tinazzi; Giovanni Abbruzzese
Journal:  CNS Drugs       Date:  2010-10       Impact factor: 5.749

7.  Use of the dopamine receptor agonist Mirapex in the treatment of Parkinson's disease.

Authors:  N V Fedorova; I P Chigir'
Journal:  Neurosci Behav Physiol       Date:  2007-07

Review 8.  Targets for neuroprotection in Parkinson's disease.

Authors:  Talene A Yacoubian; David G Standaert
Journal:  Biochim Biophys Acta       Date:  2008-10-01

Review 9.  Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.

Authors:  M Dooley; A Markham
Journal:  Drugs Aging       Date:  1998-06       Impact factor: 3.923

Review 10.  Protection against Parkinson's disease progression: clinical experience.

Authors:  Peter A LeWitt; Danette C Taylor
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.